China SXT Pharmaceuticals, Inc. (SXTC) Cash Flow Statement
Where SXTC’s cash came from and went, FY2026
March 31, 2026 · U.S. dollars- Cash from operations
- −$4.0M
- Capital expenditures
- $4 0.0% of revenue
- Free cash flow
- −$4.0M −374.5% margin
- Returned to shareholders
- —
- Change in cash
- $10.0M cash at year-end $28.2M
Cash from operations
−$4.0M
Acquisitions & other
−$1.3M
Net borrowing (repayment)
+$144,159
Shares issued
+$14.3M
Currency & other
+$881,653
Change in cash
$10.0M
Drawn to scale: where the cash came from and how it was used. Hover for values.
SXTC operating cash flow, capex and free cash flow
Operating cash flowCapital expendituresFree cash flowFCF margin (right axis)
SXTC cash flow trends, FY2017–FY2026
| Metric | Trend | Then | Latest | Change |
|---|---|---|---|---|
| Operating cash flow | $293,042FY2017 | −$4.0MFY2026 | — | |
| Capital expenditures | $186,308FY2017 | $4FY2026 | −69.7%/yr | |
| Free cash flow | $106,734FY2017 | −$4.0MFY2026 | — | |
| Free cash flow margin | 2.2%FY2017 | −374.5%FY2026 | −376.7 pts | |
| Operating cash flow / net income | 0.25FY2017 | 0.16FY2019 | −0.09 | |
| Stock-based compensation | $2FY2018 | $5.3MFY2026 | +535.3%/yr | |
| Capex / revenue | 3.8%FY2017 | 0.0%FY2026 | −3.8 pts |
Change is the average annual growth (CAGR) or the difference between the first and latest year.
SXTC cash flow by activity
OperatingInvestingFinancingChange in cash
SXTC net income vs operating cash flow
Net incomeOperating cash flow
Operating cash flow above net income usually means earnings are backed by cash (depreciation and stock-based pay are non-cash expenses).
SXTC cash flow statement
| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating activities | ||||||||||
| Net income | −$6.2M | −$3.3M | −$3.1M | −$5.9M | −$5.7M | −$2.7M | −$7.9M | $1.5M | $1.2M | $1.2M |
| Depreciation & amortization | $143,219 | $82,297 | $203,247 | $250,162 | $320,007 | $345,414 | $331,837 | $180,917 | $129,439 | $99,228 |
| Stock-based compensation | $5.3M | $0 | $352,100 | $554,571 | $2.3M | $1.3M | $5.7M | $11 | $2 | — |
| Change in working capital | −$2.4M | −$971,735 | −$381,559 | $1.4M | $1.9M | −$1.6M | $1.9M | −$1.5M | $608,992 | −$991,332 |
| Other non-cash items | −$871,145 | $1.8M | $996,691 | $3.6M | −$1.2M | $1.4M | $904,619 | $59,164 | −$5,853 | $0 |
| Cash from operating activities | −$4.0M | −$2.3M | −$1.9M | −$80,757 | −$2.4M | −$1.3M | $934,247 | $239,192 | $1.9M | $293,042 |
| Investing activities | ||||||||||
| Capital expenditures | −$4 | −$2,023 | −$7,063 | −$70,684 | −$62,490 | −$93,044 | −$406,658 | −$610,085 | −$1.1M | −$186,308 |
| Investments (net) | — | $63,516 | $26,423 | −$12,303 | −$46,909 | −$8.8M | −$5.5M | −$610,085 | −$1.1M | −$3.6M |
| Acquisitions & other investing | −$1.3M | $2,023 | $7,063 | $70,684 | $62,490 | $3.1M | $406,658 | $610,085 | $1.1M | $3.6M |
| Cash from investing activities | −$1.3M | $63,516 | $26,423 | −$12,303 | −$46,909 | −$5.8M | −$5.5M | −$610,085 | −$1.1M | −$186,308 |
| Financing activities | ||||||||||
| Dividends paid | — | — | — | — | — | — | — | −$2.4M | — | — |
| Share repurchases & issuance (net) | — | — | — | — | — | — | — | $6.5M | — | — |
| Net borrowing (repayment) | $144,159 | −$65,115 | $1.4M | $4.0M | −$1.0M | $12.4M | $5.6M | $2.6M | −$314,216 | −$50,560 |
| Shares issued | $14.3M | $2.8M | $0 | $2.2M | $3.1M | $0 | $0 | $6.5M | $0 | $0 |
| Other financing | $0 | $5.7M | −$4.0M | −$3.3M | −$445,236 | $0 | −$2.6M | −$4.1M | $0 | $0 |
| Cash from financing activities | $14.4M | $8.4M | −$2.6M | $2.9M | $1.6M | $12.4M | $3.0M | $9.0M | −$314,216 | −$50,560 |
| Summary | ||||||||||
| Net change in cash | $10.0M | $6.1M | −$5.3M | $1.8M | −$399,125 | $6.1M | −$2.0M | $8.6M | $494,682 | $54,131 |
| Cash at end of period | $28.2M | $18.1M | $12.1M | $17.4M | $13.0M | $13.4M | $7.3M | $9.3M | $560,252 | $65,570 |
| Free cash flow | −$4.0M | −$2.3M | −$1.9M | −$151,441 | −$2.4M | −$1.4M | $527,589 | −$370,893 | $869,436 | $106,734 |
| Free cash flow margin | −374.5% | −134.8% | −100.3% | −7.7% | −93.6% | −29.5% | 10.2% | −5.3% | 12.4% | 2.2% |
| Capex / revenue | 0.0% | 0.1% | 0.4% | 3.6% | 2.4% | 1.9% | 7.9% | 8.7% | 15.0% | 3.8% |
| Operating cash flow / net income | — | — | — | — | — | — | — | 0.16 | 1.62 | 0.25 |
| Jun '26 | Dec '25 | Sep '25 | Jun '25 | Dec '24 | Jun '24 | Dec '23 | Sep '23 | Jun '23 | Dec '22 | Sep '22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating activities | |||||||||||
| Net income | $163,718 | $81,858 | −$6.4M | −$3.2M | −$1.3M | −$401,284 | $3.3M | −$4.8M | −$4.8M | −$2.2M | −$747,304 |
| Depreciation & amortization | $111,119 | $55,560 | $32,100 | $16,049 | $6,879 | $78,496 | $90,281 | $102,750 | $51,375 | $82,104 | $109,966 |
| Stock-based compensation | — | −$184,462 | — | $2.8M | — | $176,050 | $176,050 | — | $138,643 | $138,643 | $138,642 |
| Change in working capital | −$1.4M | −$689,372 | −$992,509 | −$166,891 | −$104,303 | −$528,622 | −$325,965 | $352,166 | $149,032 | $709,480 | −$173,028 |
| Other non-cash items | −$1.1M | −$396,029 | $5.6M | −$378,372 | $628,075 | $10,566 | −$3.9M | $4.3M | $4.2M | $1.5M | $450,285 |
| Cash from operating activities | −$2.3M | −$1.1M | −$1.8M | −$876,283 | −$719,891 | −$664,794 | −$674,243 | −$141,629 | −$289,784 | $234,184 | −$221,439 |
| Investing activities | |||||||||||
| Capital expenditures | $0 | $0 | −$4 | −$988,154 | −$1,012 | −$3,532 | −$3,532 | $0 | −$50,568 | −$25,284 | −$20,115 |
| Acquisitions & other investing | −$326,362 | −$163,181 | −$924,555 | $525,874 | $12,498 | $23,804 | $6,924 | $9,820 | $60,388 | −$523 | $39,770 |
| Cash from investing activities | −$326,362 | −$163,181 | −$924,559 | −$462,280 | $11,486 | $20,272 | $3,392 | $9,820 | $9,820 | −$25,807 | $19,655 |
| Financing activities | |||||||||||
| Net borrowing (repayment) | — | — | — | — | — | — | — | — | — | — | −$5.5M |
| Shares issued | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other financing | $9.1M | $4.5M | $5.4M | $2.7M | $580,989 | $3.6M | $918,654 | −$2.2M | −$2.2M | $7.0M | $0 |
| Cash from financing activities | $9.1M | $4.5M | $5.4M | $2.7M | $580,989 | $3.6M | $918,654 | −$2.2M | −$2.2M | $7.0M | −$5.5M |
| Summary | |||||||||||
| Net change in cash | $7.0M | $3.5M | $3.1M | −$383,324 | −$417,477 | $3.2M | $306,083 | −$2.8M | −$3.0M | $7.2M | −$6.2M |
| Cash at end of period | $28.2M | $24.7M | $21.2M | $18.1M | $14.9M | $15.0M | $11.8M | $14.6M | $14.4M | $10.2M | $9.3M |
| Free cash flow | −$2.3M | −$1.1M | −$1.8M | −$876,283 | −$720,903 | −$664,794 | −$677,775 | −$141,629 | −$289,784 | $208,900 | −$241,554 |
| Free cash flow margin | −189.0% | −442.8% | −279.7% | — | −158.2% | −160.3% | −90.2% | −15.8% | −61.7% | 54.7% | −20.0% |
| Capex / revenue | 0.0% | 0.0% | 0.0% | — | 0.2% | 0.9% | 0.5% | 0.0% | 10.8% | 6.6% | 1.7% |
| Operating cash flow / net income | −13.83 | −13.83 | — | — | — | — | −0.20 | — | — | — | — |
Negative numbers are cash paid out. Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported; data from EODHD.
SXTC cash generation
In fiscal 2026 (ended March 31, 2026), China SXT Pharmaceuticals generated -$4.0 million of cash from operations and spent $0.0 million on capital expenditures, leaving free cash flow of -$4.0 million, −374.5% of revenue. Cash and equivalents rose by $10.0 million over the year.
Related: SXTC income statement, SXTC balance sheet. See the SXTC stock overview for the latest quote and news.
SXTC cash flow FAQ
What is China SXT Pharmaceuticals's free cash flow?
China SXT Pharmaceuticals's free cash flow was -$4.0 million in fiscal 2026: -$4.0 million of operating cash flow minus $0.0 million of capital expenditures It was -$2.3 million a year earlier..
How much cash does China SXT Pharmaceuticals generate from operations?
China SXT Pharmaceuticals generated -$4.0 million of cash from operating activities in fiscal 2026.
How much does China SXT Pharmaceuticals spend on capital expenditures?
China SXT Pharmaceuticals spent $0.0 million on capital expenditures in fiscal 2026, 0.0% of revenue, compared with $0.0 million the year before.